Drug-resistant cell strain and application thereof

By optimizing drug concentration and culture conditions to build drug-resistant cell lines, combined with high-throughput sequencing technology, the problem of long time and characteristics of drug-resistant cell models in the existing technology is solved, and more efficient construction of drug-resistant cell lines is achieved. and more in-depth research on drug resistance mechanisms provide scientific basis for clinical prediction and individualized treatment.

CN118995618APending Publication Date: 2024-11-22GUANGDONG GENERAL HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411260828.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing drug-resistant cell model has a long construction cycle, large characteristics, and is difficult to simulate the clinical tumor microenvironment. There are limitations in the study of the mechanism of acquired drug resistance of osimertinib, and more effective methods are needed to predict drug resistance risks and guide individualization. treat.

Method used

By optimizing drug concentration and culture conditions, the drug-resistant cell lines are constructed, combined with high-throughput sequencing technology, the construction time of drug-resistant cell lines is shortened, the stability and success rate is improved, and the molecular mechanism of AZD9291 resistance is deeply revealed, for clinical prediction and Treatment provides scientific evidence.

Benefits of technology

It significantly shortens the construction time of drug-resistant cell lines, improves stability and success rate, provides a research model closer to clinical conditions, deeply reveals the drug-resistant mechanism, and provides a scientific basis for individualized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995618A_ABST
    Figure CN118995618A_ABST
Patent Text Reader

Abstract

The invention discloses a drug-resistant cell strain and application thereof, and belongs to the technical field of biological medicine. The preservation number of the drug-resistant cell strain is GDMCC NO: 63812. Wherein the drug-resistant bacterial strain comprises three or more mutation sites, and the mutation sites at least comprise the following three mutation sites: KIAA 1549-BRAF, BRAF-DENND2A and CHCHD3-BRAF. Meanwhile, through a continuous high-concentration osimertinib drug screening method, the osimertinib drug-resistant cell strain PC-9 / AR is successfully constructed, and the high survival rate and stability of cells are ensured. Experimental results show that the PC-9 / AR cell shows remarkable drug resistance to AZD9291, and important experimental basis and technical support are provided for researching an osimertinib drug resistance mechanism and developing a new treatment strategy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a drug-resistant cell strain and application thereof. Background Art

[0002] Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. Epidermal growth factor receptor (EGFR) is an important driver gene of NSCLC, and the incidence of EGFR activating mutations in NSCLC patients is about 10-35%. EGFR tyrosine kinase inhibitors (EGFR-TKI) have become the standard first-line treatment for patients with EGFR mutation-positive NSCLC, significantly prolonging patients' progression-free survival and overall survival.

[0003] However, despite the significant initial efficacy of EGFR-TKI, the vast majority of patients will develop acquired resistance after 10-14 months of treatment, leading to disease progression. Among them, about 50% of the resistance is caused by the T790M mutation in exon 20 of EGFR. In order to overcome T790M-mediated resistance, third-generation irreversible EGFR-TKIs such as osimertinib (AZD9291) came into being. Osimertinib can effectively inhibit EGFR sensitive mutations and T790M resistance mutations, so that the disease control rate of T790M-positive NSCL C patients reaches more than 80%.

[0004] Although osimertinib can effectively overcome T790M-mediated drug resistance, unfortunately, it also faces the problem of acquired drug resistance. Clinically, about 20-40% of patients develop drug resistance after receiving osimertinib treatment. Therefore, in-depth research on the mechanism of acquired resistance to osimertinib and the establishment of corresponding cell models are of great significance for overcoming drug resistance and guiding clinical drug use.

[0005] At present, domestic and foreign scholars have constructed a variety of osimertinib-resistant cell models using different NSCLC cell lines, such as PC-9 / AZDR, H1975 / AZDR, etc. These models simulate the drug resistance process in patients to a certain extent and provide important tools for studying the drug resistance mechanism. However, the existing drug-resistant cell models still have some limitations: (1) The construction cycle of drug-resistant cell lines is long, usually taking months to years, which is time-consuming and labor-intensive. (2) The cell lines and induction methods used in different studies are not the same, resulting in large differences in the characteristics of the obtained drug-resistant cell lines and lack of comparability. (3) The existing models are mostly based on cell line construction, which is quite different from the tumor microenvironment in patients and has certain limitations. (4) Regarding the molecular mechanism of acquired drug resistance, the conclusions drawn by different models are not consistent and need further verification and unification. Summary of the invention

[0006] 1. Problems to be solved

[0007] In view of the problems existing in the above-mentioned prior art, the present invention provides a drug-resistant cell line and its application, which significantly shortens the construction time of the drug-resistant cell line by optimizing the drug concentration and culture conditions, improves the success rate and stability of the construction of the drug-resistant cell line, and combines high-throughput sequencing and other technologies to more comprehensively and deeply reveal the molecular mechanism of AZD9291 resistance, and provide a scientific basis for clinically predicting the risk of AZD9291 resistance and guiding individualized treatment.

[0008] 2. Technical solution

[0009] To solve the above problems, the present invention adopts the following technical solutions.

[0010] A drug-resistant cell strain, with a preservation number of GDMCC NO: 63812, whose preservation center is the Guangdong Provincial Microbial Culture Collection Center, and whose preservation address is 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, and its preservation date is February 28, 2024. In addition, the taxonomic name of the drug-resistant cell strain is human lung adenocarcinoma cell resistant strain PC9-AR. The drug-resistant bacterial strain includes three or more mutation sites, including at least the following three mutation sites: KIAA1549-BRAF, BRAF-DENND2A, and CHCH D3-BRAF.

[0011] The method for constructing a drug-resistant cell line comprises the following steps:

[0012] (1) Cell recovery: transfer the frozen cells to a centrifuge tube containing cell culture medium, discard the supernatant after centrifugation, resuspend the cells in cell culture medium, and inoculate them in a culture dish containing cell culture medium for recovery culture;

[0013] (2) Cell passaging: adding digestive enzymes to the cells after resuscitation and culture in step (1) for digestion, pipetting and mixing, and supplementing with new cell culture medium for passaging;

[0014] (3) Drug screening and drug resistance induction: The cells in the logarithmic growth phase after subculture in step (2) are transferred to a new cell culture medium for culture, and the cell proliferation inhibition rate is detected. The IC50 value is compared to determine whether the cells have achieved high drug resistance, until cells induced with high drug resistance are screened out.

[0015] Preferably, the cells frozen in step (1) are non-small cell lung cancer cell lines PC-9 with epidermal growth factor receptor mutations;

[0016] The cell culture medium in step (1) is a DMEM culture medium containing inactivated fetal bovine serum, dual antibodies and osimertinib, wherein the mass percentage of inactivated fetal bovine serum is 5-15%, the dual antibodies are penicillin and streptomycin in a mass ratio of 1:(1-8), the mass percentage of the dual antibodies is 0.5-1.5%, and the mass concentration of osimertinib is 1-5uM.

[0017] Preferably, the centrifugation parameters in step (1) are as follows: centrifugation at 600-1200 rpm for 2-10 min;

[0018] The parameters of the cell culture in step (1) are as follows: 30-40° C., 2-10% CO2 mass concentration;

[0019] The next day after cell culture in step (1), the cell morphology, density and survival rate are observed, the old cell culture medium is removed, new cell culture medium is added, and the cells are cultured until the cell confluence reaches 60-90%.

[0020] Preferably, the digestive enzyme in step (2) is one of lipase, trypsin and amylase;

[0021] The digestion parameters in step (2) are as follows: let stand for 30s-120s.

[0022] Preferably, the concentration of osimertinib in the cell culture medium in step (3) is 50-200 nM;

[0023] The method for detecting the cell proliferation inhibition rate in step (3) is as follows:

[0024] The dilute cells in the logarithmic phase were digested with 0.20-0.30% trypsin by mass to prepare a single-cell suspension and count the cells. The cells were then inoculated in a 96-well plate and incubated with different concentrations of osimertinib for 24-96 hours. MTT solution was added and the reaction was terminated after further incubation for 2-6 hours. DMSO was used to dissolve the crystals and the OD value was measured.

[0025] Preferably, when a cell culture medium is used for culturing in step (3), the cell culture medium is replaced every 2-3 days.

[0026] Preferably, the method for screening out cells induced with high drug resistance in step (3) is as follows: a portion of the cells are transferred to a drug-free cell culture medium and cultured for 10-20 days, and the IC50 value is detected again using the MTT method. If the IC50 value remains unchanged, the construction is successful.

[0027] Preferably, the method for screening out highly drug-resistant induced cells in step (3) further comprises morphological observation and gene mutation detection; wherein the morphological observation is as follows: using an inverted fluorescence microscope to observe the morphological differences between the drug-resistant cell strain and the parental cell;

[0028] The gene mutation detection is as follows: high-throughput gene sequencing technology is used to detect the gene mutations of drug-resistant cell lines and parental cells.

[0029] A drug-resistant cell line as described above is used in osimertinib resistance.

[0030] Preferably, the drug-resistant cell line is used to construct an in vivo and in vitro osimertinib-resistant tumor model of human non-small cell lung cancer.

[0031] 3. Beneficial effects

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] (1) Shorten the construction cycle: Traditional methods for constructing drug-resistant cell lines usually take a long time, which may take months to years. The present invention significantly shortens the construction time of drug-resistant cell lines by optimizing drug exposure and culture conditions (the construction of drug-resistant cell lines usually takes months or years. Specifically, low-concentration drug-resistant strains may take several years to reach the drug resistance standard, while medium-concentration construction may take several months to several years. High-concentration treatments often directly kill cells, making it impossible to continue to construct drug-resistant strains), thereby improving experimental efficiency.

[0034] (2) Improved stability and success rate: In the prior art, different laboratories use different cell lines and methods, resulting in large differences in the characteristics of drug-resistant cell lines. The present invention provides a standardized construction method to ensure the stability and construction success rate of drug-resistant cell lines.

[0035] (3) Better simulation of clinical conditions: Existing models are mostly based on cell lines, which are difficult to fully simulate the tumor microenvironment in patients. The present invention optimizes the culture conditions to make the drug-resistant cell lines closer to clinical drug resistance, thereby improving the clinical relevance of the research results.

[0036] (4) Providing a reliable drug screening platform: The drug-resistant cell lines constructed by the present invention can be used to screen and evaluate the efficacy of new drugs or drug combinations, providing a reliable platform for overcoming AZD9291 resistance.

[0037] (5) In-depth revelation of drug resistance mechanism: Through high-throughput sequencing and other technical means, the present invention can more comprehensively reveal the molecular mechanism of AZD9291 resistance and provide a scientific basis for future research and treatment strategies.

[0038] (6) Clinical application potential: The drug-resistant cell line constructed by the present invention is not only of great value in laboratory research, but can also be used to guide the formulation of clinical individualized treatment strategies and has broad application prospects.

[0039] In summary, the present invention is significantly superior to the prior art in terms of construction efficiency, stability, clinical simulation and application potential of drug-resistant cell lines, and provides important scientific and clinical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 This is a graph showing the inhibition of PC-9 parent cell proliferation by the drug AZD9291 of the present invention;

[0041] Figure 2 It is a cell activity diagram of PC-9 / AR cells and PC-9 cells under the action of different concentrations of AZD9291 in the present invention;

[0042] Figure 3 is a diagram of genome variation detection results in the present invention;

[0043] Figure 4 It is a diagram of the sequencing results of CHCHD3_BRAF_1 in the present invention;

[0044] Figure 5 This is a diagram of the sequencing results of CHCHD3_BRAF_2 in the present invention;

[0045] Figure 6 This is a diagram of the sequencing results of DENND2A_BRAF_1 in the present invention;

[0046] Figure 7 This is a diagram of the sequencing results of DENND2A_BRAF_2 in the present invention;

[0047] Figure 8 is a diagram of the sequencing results of EGFR-19Del in the present invention;

[0048] Fig. 9 This is a diagram of the sequencing results of KIAA1549_BRAF_1 in the present invention;

[0049] Fig.10 This is a diagram of the sequencing results of KIAA1549_BRAF_2 in the present invention;

[0050] Fig.11 It is a diagram of the culture state of PC-9 / AR cells after construction in the present invention. DETAILED DESCRIPTION

[0051] The present invention is further described below in conjunction with specific embodiments.

[0052] This study used the PC-9 cell line, which carries the EGFR exon 19 E746-A750 deletion mutation. The cells were cultured in DMEM medium containing 10% inactivated fetal bovine serum, 1% double antibody (100U / mL penicillin and 100μg / mL streptomycin), and 2μM AZD9291 was added to the medium to form a drug-containing cell culture medium. The cell culture dish was placed in an electric thermostatic cell culture incubator at 37°C and 5% CO2. By optimizing the recovery, subculture and cryopreservation methods of AZD9291-resistant cell lines, this study provides a reliable experimental basis for studying the resistance mechanism and developing new treatment strategies. These methods ensure the survival rate and stability of the cell lines, which is conducive to subsequent biomedical research.

[0053] Example 1

[0054] In the process of studying AZD9291-resistant cell lines, cell recovery is a key step to ensure that cells can recover and continue to grow after freezing. The following are the optimized cell recovery steps:

[0055] The steps for cell recovery are as follows:

[0056] a) Thawing: Take out the frozen cells from the -80℃ ultra-low temperature freezer, quickly put them into a 37℃ water bath (30℃ or 40℃ can be used), and shake gently to accelerate the thawing process. Keep the top of the cryovial above the liquid level to avoid contamination.

[0057] b) Disinfection: After the cell cryopreservation solution is completely thawed, spray the cryopreservation tube with 75% alcohol for external disinfection to ensure aseptic operation.

[0058] c) Transfer: Quickly transfer the cell suspension to a 15 mL centrifuge tube containing 9 mL of cell culture medium for subsequent processing.

[0059] d) Centrifugation: Centrifuge at 800 rpm for 5 min at room temperature to separate cells from the cryopreservation solution.

[0060] e) Resuspension: Discard the supernatant and resuspend the cells with 1 mL of drug-containing cell culture medium (containing AZD9291) to ensure that the cells obtain sufficient nutrients and drug stimulation.

[0061] f) Inoculation: Inoculate the resuspended cells in a cell culture dish containing 7 mL of cell culture medium, gently pipette to evenly distribute the cell suspension, and place the culture dish in a cell culture incubator at 37° C. and 5% CO 2 for culture.

[0062] g) Observation and maintenance: The next day, remove the cells and observe their morphology, density and survival rate. Aspirate the old culture medium, add 8 mL of fresh drug-containing culture medium, and continue culturing to ensure that the cells are in the best growth state.

[0063] It should be noted that the cell culture medium is a DMEM medium containing inactivated fetal bovine serum, double antibodies and osimertinib, wherein the mass percentage of inactivated fetal bovine serum is 10%, wherein the double antibodies are penicillin and streptomycin in a mass ratio of 1:1, wherein the mass percentage of the double antibodies is 1.0%, and wherein the mass concentration of osimertinib is 2uM. Other proportional relationships can also be achieved, but the above are optimized data values.

[0064] By optimizing the cell recovery process, the high survival rate and viability of AZD9291-resistant cell lines were ensured. This improved step provides a solid foundation for subsequent cell passage and experiments, ensuring the reliability and reproducibility of experimental results.

[0065] Example 2

[0066] Cell culture

[0067] a) Cell line selection: The cell line used in this study was PC-9, which has an EGFR exon 19 E746-A750 deletion mutation and is an ideal model for studying the drug resistance mechanism of non-small cell lung cancer (NSCLC).

[0068] b) Subculture conditions: When the cells grow to cover 80% of the surface area in the culture dish, subculture is performed. At this time, the cells are in the logarithmic growth phase and have the best vitality.

[0069] c) Medium preparation and replacement: After aspirating the old medium, wash the cells once with 3 mL of calcium- and magnesium-free PBS to remove residual medium and metabolic waste.

[0070] Example 3

[0071] Digestion and passaging steps

[0072] a) Digestive enzyme treatment: Add 1 mL of 0.25% trypsin solution containing 2% EDTA, and ensure that the enzyme solution evenly covers the cell surface. Let it stand for 1 minute, and observe the cell status during this period.

[0073] b) Cell observation: Observe the cells under a microscope. When the cells appear as round particles or the bottom of the culture dish appears cloudy, gently shake the culture dish to promote cell detachment.

[0074] c) Stop digestion: Add 2 mL of fresh culture medium to stop the action of the digestive enzymes and gently pipette the cells to mix to ensure that the cells are evenly distributed.

[0075] d) Cell dilution and inoculation: Discard some cells in proportion to the required cell density. Replenish the culture medium to 8 mL and continue culturing or transfer the cells to a new culture dish for expansion.

[0076] Notes on cell culture

[0077] Aseptic operation: Ensure that all operations are performed under a sterile environment and use a biosafety cabinet to reduce the risk of contamination.

[0078] Microscopic examination: Regularly check the growth status of cells under a microscope to confirm that there is no bacterial or fungal contamination.

[0079] Medium status: Observe the color change of the medium to ensure that the cells are growing in a healthy state. Yellowing of the medium is usually the result of the accumulation of acidic metabolites and needs to be replaced in time.

[0080] By optimizing the cell culture and passaging steps, the healthy growth and stability of PC-9 cells were ensured. These improvements not only improved the cell survival rate and passaging efficiency, but also provided a reliable basis for subsequent experimental research.

[0081] Cell cryopreservation is an important step in preserving cell lines in the laboratory to ensure that cells remain viable and functional for a long time. The following are the optimized cell cryopreservation steps:

[0082] Example 4

[0083] Cell Cryopreservation Steps

[0084] a) Prepare for digestion: First, remove the old culture medium from the cells and wash the cells once with 3 mL of calcium- and magnesium-free PBS to remove residual culture medium and metabolic waste. Then, add 1 mL of 0.25% trypsin solution containing 2% EDTA by mass, ensuring that the enzyme solution evenly covers the cell surface.

[0085] b) Digestion and collection: After the cells are fully digested and fall off the wall of the culture dish, add 2 mL of fresh cell culture medium to terminate the digestion. Gently pipette to mix the cell suspension, transfer it to a 15 mL centrifuge tube, and centrifuge at 800 rpm for 5 minutes at room temperature.

[0086] c) Preparation of cryopreservation solution: Prepare the cryopreservation solution in advance and mix it evenly according to the mass ratio of DMSO: 1640 culture medium: fetal bovine serum = 1:2:7. Make sure that the cryopreservation solution has reached room temperature before use to prevent sudden temperature changes from damaging the cells.

[0087] d) Resuspend cells: After centrifugation, discard the supernatant, add 2 mL of freezing solution (70% serum + 20% cell culture medium + 10% DMSO), and gently pipette to mix the cell pellet. Transfer 1 mL of cell suspension to a labeled freezing tube, and keep at least 2 tubes for each cell line to ensure backup.

[0088] e) Programmed cooling: Place the cryopreservation tubes containing cells in a programmed cooling box and place them in a -80°C ultra-low temperature refrigerator for initial freezing. After 24 hours, transfer the cryopreservation tubes to liquid nitrogen for long-term storage to ensure cell viability and stability.

[0089] Precautions

[0090] Aseptic operation: Aseptic operation should be maintained throughout the process, using sterile instruments and environment to avoid cell contamination.

[0091] Temperature control: Ensure that the freezing solution and cell suspension are at similar temperatures when mixed to reduce the impact of temperature stress on cells.

[0092] Recording and labeling: Record the cell line name, freezing date and cell density of each cryovial in detail, and ensure that the cryovials are clearly labeled for subsequent retrieval and use.

[0093] By optimizing the cell freezing steps, the long-term preservation and high survival rate of AZD9291-resistant cell lines were ensured. These improvements provide reliable cell resources for subsequent experimental studies and ensure the stability and repeatability of experimental results.

[0094] Example 5

[0095] Method for constructing AZD9291-resistant cell line

[0096] The MTT assay is an important method for evaluating cell proliferation and drug inhibition effects. The following are the optimized steps:

[0097] a) Cell preparation: When the cells are in the logarithmic growth phase, trypsin with a mass concentration of 0.25% is used for digestion. The cells are made into a single cell suspension using a culture medium containing 10% fetal bovine serum, and the cells are counted.

[0098] b) Cell seeding: PC-9 cells were seeded in 96-well plates, with 5 x 10 3 Ensure that the cells are evenly distributed to improve the accuracy of the experiment.

[0099] c) Drug treatment: After the cells adhere to the wall (choose the next day), discard the old culture medium. Divide the cells into a control group (without drugs) and an experimental group (different concentrations of AZD9291), set up 6 replicate wells in each group, and add 200 μL of culture medium to each well. Place the culture plate in a constant temperature incubator at 37°C and 5% CO2 and incubate for 48 hours.

[0100] d) MTT staining: After incubation for 48 hours, remove the old culture medium. Add 200 μL of a solution containing 5 mg / mL MTT (MTT: PBS = 1:9) to each well and incubate for 4 hours in the dark. Carefully discard the MTT solution, add 200 μL PBS to wash once, and then discard the PBS. Add 150 μL DMSO to dissolve the crystals formed by MTT, and shake for 10 minutes in the dark.

[0101] e) OD value determination: Use a microplate reader to measure the optical density (OD value) of each well at a wavelength of 490 nm and record the results.

[0102] f) IC50 calculation: Calculate the average OD value of each group and calculate the cell growth inhibition rate using the formula:

[0103] Inhibition rate = 1-(OD value of experimental group-OD value of blank control group / OD value of control group-OD value of blank control group) x 100%. GraphPad Prism software was used to calculate the IC50 value and the resistance index (RI), where RI is the ratio of IC50 of resistant cells to IC50 of parent cells. RI grading: 1-5 is low resistance, 5-15 is moderate resistance, and 15 or more is high resistance. A cell growth fitting curve of the logarithm of drug concentration and inhibition rate was drawn.

[0104] Result analysis and construction of drug-resistant cell lines

[0105] Continuous high-concentration screening: When the cells are in the logarithmic growth phase, culture them in a medium containing 100nM AZD9291, and replace the drug-containing medium or subculture every 2-3 days. Use the MTT method to detect the IC50 value every two weeks. When the IC50 value exceeds 15 times the IC50 value of the parental cells, the cells are considered to be highly resistant. Transfer a portion of the cells to a drug-free medium and culture for two weeks, and then detect the IC50 value again. If the value remains unchanged, the drug-resistant strain is successfully constructed.

[0106] Morphological observation: An inverted fluorescence microscope was used to observe the morphological differences between drug-resistant cell lines and parental cells. Drug-resistant cell lines usually show characteristics such as increased cell volume and blurred boundaries.

[0107] Gene mutation detection: High-throughput sequencing technology is used to detect the genetic mutations of drug-resistant cell lines and parental cells. Common mutations include fusion genes such as KIAA1549-BRAF and BRAF-DENND2A.

[0108] By optimizing the construction method of AZD9291-resistant cell lines, the accuracy and repeatability of the experiment were ensured. The optimization of the MTT experiment improved the ability to evaluate the inhibitory effect of drugs, providing a solid foundation for subsequent research on drug resistance mechanisms. The successful construction of drug-resistant cell lines provides an important experimental model for the development of new treatment strategies.

[0109] MTT assay for parental cells

[0110] Before the parental cells were induced by drugs, the MTT method was used to detect the proliferation inhibition rate of AZD9291 on NSCLC cell lines and the IC50 was calculated.

[0111] Continuous high concentration screening

[0112] When the cells are in the logarithmic growth phase, culture them in a medium containing 100 nM AZD9291. Change the drug-containing medium or subculture every 2 days. Use the MTT method to calculate the IC50 value every two weeks. When the IC50 value exceeds the IC50 value of the parental cells by 15 times (drug resistance index greater than 15), the cells are considered to be highly resistant. Then take a part of the cells and culture them in a drug-free medium for two weeks. Use the MTT method to calculate the IC50 value again. If the value remains unchanged, the drug-resistant strain has been successfully constructed.

[0113] Observation of the morphology of drug-resistant cell lines using an inverted fluorescence microscope

[0114] The morphology and growth of the resistant cell lines were observed under an inverted microscope and compared with the parental cell line.

[0115] MTT method drug concentration setting and drug resistance index

[0116] Selection of AZD9291 drug concentration: The highest concentration for PC-9 cells was 4uM, and a total of 8 gradient concentrations were diluted to obtain final drug concentrations of 4000nM, 2000nM, 1000nM, 500nM, 100nM, 50nM, 10nM, and 5nM. A drug-free culture medium was set as a control group.

[0117] Statistical analysis

[0118] IC50 was calculated using Graphpad Prism statistical software, and fitting curves were drawn using GraphPad Prism 10.1.2. Data were expressed as mean ± SEM, and Student's T test was used to compare whether the two groups of data were statistically different, with P < 0.05 as a statistically significant difference.

[0119] result:

[0120] The preservation number of the drug-resistant cell strain is GDMCC NO: 63812, and its preservation center is Guangdong Microbial Culture Collection Center. Its preservation address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and its preservation date is February 28, 2024.

[0121] Combination Figure 1As shown in Table 1, when studying the effect of AZD9291 on PC-9 cell proliferation, the MTT method can effectively evaluate the inhibitory effect of the drug and calculate the half inhibitory concentration (IC50). Cell line: PC-9 cell line, which has the EGFR 19 exon E746-A750 deletion mutation, is an ideal model for studying the drug resistance mechanism of non-small cell lung cancer (NSCLC). Drug concentration: Set the final concentration of AZD9291 to 5nM, 10nM, 50nM, 100nM, 500nM, 1000nM, 2000nM and 4000nM to evaluate the inhibitory effect of different concentrations on cell proliferation. The accuracy and repeatability of the experiment were ensured by optimizing the steps of detecting PC-9 parental cells by MTT method. This method provides a reliable basis for evaluating the inhibitory effect of AZD9291 on the proliferation of NSCLC cell lines and provides important reference data for subsequent drug resistance mechanism research. At the same time, the IC50 of PC-9 parental cells to AZD9291 was (0.169±0.039) μM analyzed by Graphpad Prism.

[0122] Table 1 Inhibition rate of AZD9291 on PC-9 proliferation (x±s)

[0123]

[0124]

[0125] Establishment of AZD9291-resistant cell line PC-9 / AR: We used the method of continuous high concentration, selected 100nM AZD9291 to act on the cells, and maintained the culture concentration. At the beginning, cell growth was significantly inhibited, and the number of cell deaths was relatively large. The medium was changed every 3 days. When the cells recovered 90% confluence, 1:3 passage was performed. IC50 was calculated by MTT method every 2 weeks, and the changes of IC50 were observed. When IC50 was more than 10 times that of the parent cell line IC50, a part of the cells was cultured in drug-free medium for 2 weeks. The inhibition rate and IC50 calculated by MTT detection did not decrease. PC-9 cells were passaged 19 times and induced for a total of 6 months. The cells were named PC9 / AZD9291 resistance, abbreviated as PC-9 / AR. After the successful construction of the drug-resistant cell line, it was directly cultured in AZD9291 medium with a maintenance concentration of 1.5μM. The experimental drug-resistant cell lines were cultured in drug-free medium for more than 2 weeks before being used in the experiment.

[0126] PC-9 / AR cell morphology: combined Fig.11The two PC-9 cells were placed under an inverted fluorescence microscope for observation. Under the microscope, both PC-9 and PC-9 / AR cells showed epithelial-like cell monolayer growth, uniform cell size, clear PC-9 boundaries, mostly round, and tended to grow in clusters; while PC-9 / AR cells were slightly larger, with slightly blurred boundaries, growing in clusters, and some cells were oval or irregular spindle-shaped. The morphological differences between PC-9 / AR cells and PC-9 cells, especially the increase in volume and irregular morphology, suggest that the development of drug resistance may be accompanied by the reorganization of cell morphology and structure. These morphological changes may be related to the genetic mutation of cells and changes in metabolic pathways, providing important clues for further research on the mechanism of drug resistance. The morphological analysis of PC-9 / AR cells can provide a reference for subsequent functional research and drug development.

[0127] MTT method was used to compare the effects of AZD9291 on the activity of PC-9 and PC-9 / AR cells: PC-9 resistant cells were treated with AZD9291 at final concentrations of 5nM, 10nM, 50nM, 100nM, 500nM, 1000nM, 2000nM, and 4000nM for 48h, and the inhibition rate of cell proliferation by different concentrations of AZD9291 was detected (see Table 2), and the effects of AZD9291 on the activity of PC-9 and PC-9 / AR cells were compared (see Table 3). Figure 2 ). Cell activity of PC-9 cells and PC-9 / AR cells under different concentrations of AZD9291: PC-9 cells: As the concentration of AZD9291 increased, the activity of PC-9 cells decreased significantly, with an IC50 of 0.169±0.039μM. PC-9 / AR cells: In contrast, the sensitivity of PC-9 / AR cells to AZD9291 was significantly reduced, with an IC50 of 3.982±0.514μM, showing obvious drug resistance. Drug resistance index: The drug resistance index of PC-9 / AR cells to AZD9291 was 23.56, which is highly resistant. This indicates that PC-9 / AR cells have undergone significant biological changes under long-term drug pressure. Morphological changes: Morphological changes in PC-9 / AR cells, such as increased volume and blurred boundaries, may be related to the development of their drug resistance. Gene mutation: Further whole genome sequencing showed that fusion genes such as KIAA1549-BRAF and BRAF-DENND2A appeared in PC-9 / AR cells. These mutations may be related to the drug resistance mechanism. The MTT method was used to compare the effects of AZD9291 on PC-9 and PC-9 / AR cells, and the drug resistance characteristics of PC-9 / AR cells and their potential molecular mechanisms were clarified. These findings provide important experimental basis for in-depth research on the drug resistance mechanism of AZD9291 and the development of new treatment strategies.

[0128] At the same time, with the increase of AZD9291 concentration, the activity of PC-9 and PC-9 / AR cells was gradually inhibited. According to the OD values ​​obtained in the MTT experiment, the IC50 of PC-9 and PC-9 / AR cells were calculated to be 0.169±0.039μM and 3.982±0.514μM, respectively. The resistance index of PC-9 / AR to AZD9291 was 23.56 (highly resistant).

[0129] This significant difference in drug resistance suggests that PC-9 / AR cells undergo important biological changes under long-term AZD9291 exposure. To further reveal the mechanism of drug resistance, high-throughput gene sequencing technology was used to conduct a comprehensive genetic variation analysis of PC-9 and PC-9 / AR cells. The results showed that compared with PC-9 parental cells, multiple gene fusion events occurred in PC-9 / AR cells, including KIAA1549-BRAF, BRAF-DENND2A, and CHCHD3-BRAF. The emergence of these gene fusions may be closely related to the development of cell resistance.

[0130] Specifically, the frequency of KIAA1549-BRAF fusion in PC-9 / AR cells reached 25.1%, the frequency of BRAF-DENND2A fusion was 17.7%, and the frequency of CHCHD3-BRAF fusion was 5.0%. These fusion genes may lead to abnormal activation of downstream signaling pathways, thereby conferring resistance to AZD9291.

[0131] Table 2 Inhibition rate of AZD9291 on PC-9 / AR cell proliferation (x±s)

[0132]

[0133] Whole genome sequencing to detect gene mutations in PC-9 and PC-9 / AR cells

[0134] Using a high-throughput gene sequencing platform, target region capture and high-depth sequencing were performed on all exon regions of 312 genes, introns, promoters or fusion breakpoint regions of 38 genes, and coding regions of 709 genes, and four types of mutations in tumor genes (including point mutations, small fragment insertions and deletions, copy number variations, and currently known fusion genes) were detected.

[0135] The data showed that compared with the parental cells, PC-9 / AR cells had KIAA1549-BRAF, BRAF-DENND2A, and CHCHD3-BRAF fusions (see Table 3, e.g. Figures 3 to 10). Among them, the KIAA1549-BRAF fusion frequency reached 25.1%, the BRAF-DENND2A fusion frequency was 17.7%, and the CHCHD3-BRAF fusion frequency was 5%. General cell lines do not carry these fusion genes. These fusion genes are unique to this cell line after it is successfully constructed. The results of whole genome sequencing showed that compared with the parental cell PC-9, significant gene mutations occurred in PC-9 / AR cells, especially in fusion genes. These gene mutations may be closely related to the cell's resistance to AZD9291. Specifically, the KI AA1549-BRAF fusion frequency detected in PC-9 / AR cells reached 25.1%, the BRAF-DENND2A fusion frequency was 17.7%, and the CHCHD3-BR AF fusion frequency was 5%. The emergence of these fusion genes suggests that the cells may have undergone complex gene recombination events during the development of drug resistance. KIAA1549-BRAF fusion is often associated with abnormal BRAF signaling pathway activation, which may lead to enhanced cell proliferation and survival, thereby conferring cell resistance to AZD9291. The detection of BRAF-DENND2A and CH CHD3-BRAF fusions further supports the hypothesis that these fusion genes may be involved in the formation of resistance through different mechanisms. The functional effects of these gene variants require further experimental validation to determine their specific mechanisms of action in resistance. In-depth study of the functions of these fusion genes can provide potential targets for the development of new targeted therapeutic strategies to overcome the therapeutic challenges posed by AZD9291 resistance. Future studies can focus on the functional validation of these gene variants, the analysis of related signaling pathways, and possible drug targeting strategies, in order to provide new solutions to the problem of resistance.

[0136] Table 3 Test results

[0137]

[0138] Finally, we conducted clinical verification:

[0139] Volunteer 1: Genetic testing was performed on a tumor tissue sample from a patient numbered 1901197. The p.E746_A750del mutation of the EGFR gene was detected in the patient's tumor tissue, which indicates that the patient is sensitive to EGFR inhibitors such as afatinib, erlotinib, gefitinib, icotinib, dacomitinib and osimertinib. NRAS gene amplification was detected in the patient's tumor tissue, which indicates that the patient is resistant to EGFR inhibitors such as afatinib, erlotinib, gefitinib, icotinib and osimertinib or needs to be carefully selected. EGFR gene amplification was detected in the patient's tumor tissue, and the current research conclusions on the relationship between this mutation and the efficacy of EGFR inhibitors are inconsistent. RICTOR gene amplification was also detected in the patient's tumor tissue, which indicates that the patient may be sensitive to mTOR inhibitors such as CC-223 and MLN0128.

[0140] Volunteer 2: A tumor drug gene detection report for patient 1901198, the main findings are: EGFR gene: The EGFR gene was detected to have p.E746_A750del mutation (exon 19 deletion), with a frequency of 48.3%, suggesting that the patient may be sensitive to first-generation to third-generation EGFR inhibitors, such as afatinib, erlotinib, gefitinib, icotinib, dacomitinib and osimertinib. At the same time, the EGFR gene was amplified, but its relationship with the efficacy of EGFR inhibitors has not yet been determined. Fusion gene: The KIAA1549-BRAF fusion gene was detected with a frequency of 25.1%. This fusion gene may lead to resistance to EGFR inhibitors, but the patient may be sensitive to trametinib. NRAS gene: NRAS gene amplification was detected, suggesting that the patient may be resistant to EGFR inhibitors such as afatinib, erlotinib, gefitinib, icotinib and osimertinib or need to be selected with caution. RICTOR gene: RICTOR gene amplification was detected, suggesting that the patient may be sensitive to mTOR inhibitors such as CC-223 and MLN0128. Other gene mutations: The report also lists more than 40 other gene mutations in detail, and analyzes the clinical significance of some mutations. Chemotherapy drugs: Based on the patient's genetic test results, the report predicts the sensitivity and toxic side effects of some chemotherapy drugs to the patient, providing a reference for clinical medication.

[0141] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.

[0142] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A drug-resistant cell line, characterized in that: The preservation number of the drug-resistant cell strain is GDMCC NO: 63812, and its preservation center is Guangdong Microbial Culture Collection Center. Its preservation address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and its preservation date is February 28, 2024.

2. The drug-resistant cell line according to claim 1, characterized in that: The taxonomic name of the drug-resistant cell strain is human lung adenocarcinoma cell resistant strain PC9-AR; The drug-resistant bacterial strain includes three or more mutation sites, including at least the following three mutation sites: KIAA1549-BRAF, BRAF-DENND2A, and CHCHD3-BRAF.

3. Use of the drug-resistant cell line according to any one of claims 1 to 2 in osimertinib resistance.

4. Use of the drug-resistant cell line according to claim 3 in constructing an in vivo and in vitro osimertinib-resistant tumor model of human non-small cell lung cancer.

Citation Information

Patent Citations

  • Human lung adenocarcinoma osimertinib drug-resistant cell strain PC-9 OR and application thereof

    CN118599775A

  • AU2020103247A4